Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.53 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.53 |
| ▸ | AHCY | P23526 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 4/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22348794 | 1.00 | POLB (0.54) | POLBENPP1P2RY1AHCYDOT1L | |
| SCHEMBL21162566 | 1.00 | POLB (0.54) | POLBENPP1P2RY1AHCYDOT1L | |
| SCHEMBL22348864 | 0.95 | POLB (0.51) | POLBENPP1P2RY1AHCYDOT1L | |
| SCHEMBL22348862 | 0.95 | POLB (0.51) | POLBENPP1P2RY1AHCYDOT1L | |
| SCHEMBL21162568 | 0.95 | POLB (0.51) | POLBENPP1P2RY1AHCYDOT1L | |
| SCHEMBL23187796 | 0.93 | POLB (0.56) | POLBENPP1P2RY1P2RY12P2RY2 | |
| SCHEMBL22348860 | 0.93 | POLB (0.56) | POLBENPP1P2RY1P2RY12P2RY2 | |
| SCHEMBL19821278 | 0.92 | POLB (0.54) | POLBENPP1P2RY1P2RY2DTYMK | |
| SCHEMBL19821262 | 0.92 | POLB (0.54) | POLBENPP1P2RY1P2RY2DTYMK | |
| SCHEMBL21162567 | 0.92 | POLB (0.55) | POLBENPP1P2RY1DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139525-A1 | NUCLEOTIDE PRODRUGS | CERECOR INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210101923-A1 | NUCLEIC ACID PRODRUGS | AVALO THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10745435-B2 | Nucleic acid prodrugs | CERECOR, INC. (US) | 2020-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139525-A1 | NUCLEOTIDE PRODRUGS | FPGS, DPYD, NME4 | POLB 110/4885ENPP1 113/4885P2RY1 294/4885 |
| US-20210101923-A1 | NUCLEIC ACID PRODRUGS | NUDT1, PNP, TYMP | POLB 82/4885ENPP1 30/4885P2RY1 123/4885 |
| US-10745435-B2 | Nucleic acid prodrugs | POLRMT, FPGS, POLN | POLB 11/4885ENPP1 277/4885P2RY1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.